ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

LIALDA
Colorectal disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

LIALDA Rx

Generic Name and Formulations:
Mesalamine 1.2g; del-rel tabs.

Company:
Shire US, Inc.

Therapeutic Use:

Indications for LIALDA:

To induce remission in active, mild-to-moderate ulcerative colitis; and to maintain remission of ulcerative colitis.

Adult:

≥18yrs: Swallow whole with a meal. 2.4–4.8g once daily for up to 8 weeks. Maintenance: 2.4g once daily.

Children:

<18yrs: not established.

Warnings/Precautions:

Sulfasalazine allergy. Upper GI tract obstruction (eg, pyloric stenosis) may delay onset of action. Monitor for mesalamine-induced acute intolerance syndrome; discontinue if suspected. Conditions predisposing to myocarditis or pericarditis. Renal or hepatic impairment. Monitor renal function prior to and periodically during therapy. Elderly (monitor CBCs). Pregnancy (Cat.B). Nursing mothers.

Interactions:

Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk of blood disorders with azathioprine or 6-mercaptopurine. May cause elevated test results in measuring urinary normetanephrine.

Pharmacological Class:

Aminosalicylate.

Adverse Reactions:

Ulcerative colitis, headache, flatulence, abnormal LFTs, abdominal pain; acute intolerance syndrome (cramping, bloody diarrhea, fever, headache, rash), renal impairment, cardiac hypersensitivity reactions, pancreatitis (rare).

Generic Availability:

YES

How Supplied:

Tabs—120

Sign Up for Free e-Newsletters

CME Focus